Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF

Journal of Hematology & Oncology

Fazlul H Sarkar²  Adhip PN Majumdar³  Edi Levi¹  Sanchita Roy³ 

[1] Departments of Pathology, Wayne State University, Detroit, MI, 48201, USA;Departments of Pathology and Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 740 HWCRC, 4100 JohnR Street, Detroit, MI, 48201, USA;Departments of Internal Medicine, Wayne State University, Detroit, MI, 48201, USA

关键词: Methylation;    CDF;    Colon cancer;    MiR-34c;    MiR34a;   

Others  :  822115
DOI  :  10.1186/1756-8722-5-58

 received in 2012-08-09, accepted in 2012-09-16,  发布年份 2012

【 摘 要 】

Background

Colorectal Cancer (CRC) is one of the leading causes of death worldwide. Numerous cellular events, including deregulated expression of microRNAs (miRNAs), specifically the family of miR-34 consisting of miR-34a, b and c, is known to regulate the processes of growth and metastasis.

Methods

We evaluated the expression of miR-34 in formalin-fixed paraffin-embedded (FFPE) human colon cancer tissue specimens compared to normal colonic mucosa. Moreover, we also assessed the expression of miR-34 in colon cancer cell lines treated with our newly developed synthetic analogue of curcumin referred as difluorinated curcumin (CDF) compared to well known inhibitor of methyl transferase.

Results

We found that the expression of miR-34a and miR-34c was down-regulated in colon cancer specimens compared to normal colonic mucosa and the loss of expression was also consistent with data from colon cancer cell lines. This down-regulation was attributed to promoter hypermethylation, because we found that the treatment of colon cancer cells with 5-aza-2´-deoxycytidine, a methyltransferase inhibitor, markedly induced the levels of miR-34a and miR-34c expression. Likewise, CDF was very effective in the re-expression of miR-34a and miR-34c, which was consistent with inhibition of cell growth of both chemo-sensitive and chemo-resistant colon cancer cells. The re-expression of miR-34 led to a marked reduction in the expression of its target gene, Notch-1.

Conclusion

The loss of expression of miR-34 in colon cancer is in part due to promoter hypermethylation of miR-34, which can be re-expressed with our novel agent CDF, suggesting that CDF could be a novel demethylating agent for restoring the expression of miR-34 family, and thus CDF could become a newer therapeutic agent for the treatment of colon cancer.

【 授权许可】

   
2012 Roy; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
• [2]Welch JP, Donaldson GA: The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979, 189:496-502.
• [3]Dean M, Fojo T, Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
• [4]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
• [5]Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
• [6]Garzon R, Calin GA, Croce CM: MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179.
• [7]Liu C, Tang DG: MicroRNA regulation of cancer stem cells. Cancer Res 2011, 71:5950-5954.
• [8]Todaro M, Francipane MG, Medema JP, Stassi G: Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010, 138:2151-2162.
• [9]Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al.: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011, 17:211-215.
• [10]Tazawa H, Tsuchiya N, Izumiya M, Nakagama H: Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 2007, 104:15472-15477.
• [11]Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T: Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 2011, 300:197-204.
• [12]Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY: MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007, 67:8433-8438.
• [13]Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al.: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752.
• [14]Yamakuchi M, Lowenstein CJ: MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009, 8:712-715.
• [15]Yamakuchi M, Ferlito M, Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 2008, 105:13421-13426.
• [16]Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, et al.: MicroRNAs impair MET-mediated invasive growth. Cancer Res 2008, 68:10128-10136.
• [17]Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al.: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007, 26:731-743.
• [18]Padhye S, Yang H, Jamadar A, Cui QC, Chavan D, Dominiak K, et al.: New difluoro Knoevenagel condensates of curcumin, their Schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm Res 2009, 26:1874-1880.
• [19]Padhye S, Banerjee S, Chavan D, Pandye S, Swamy KV, Ali S, et al.: Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 2009, 26:2438-2445.
• [20]Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, et al.: Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010, 70:3606-3617.
• [21]Ali S, Ahmad A, Aboukameel A, Bao B, Padhye S, Philip PA, et al.: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett 2012, 319:173-181.
• [22]Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, et al.: Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011, 6:e17850.
• [23]Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, et al.: Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012, 72:335-345.
• [24]Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH, et al.: Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 2011, 28:827-838.
• [25]Kanwar SS, Yu Y, Nautiyal J, Patel BB, Majumdar AP: The Wnt/beta-catenin pathway regulates growth and maintenance of colonospheres. Mol Cancer 2010, 9:212. BioMed Central Full Text
• [26]Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP: Elimination of Colon Cancer Stem-Like Cells by the Combination of Curcumin and FOLFOX. Transl Oncol 2009, 2:321-328.
• [27]Yu Y, Kanwar SS, Patel BB, Oh PS, Nautiyal J, Sarkar FH, et al.: MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFbetaR2) in colon cancer cells. Carcinogenesis 2012, 33:68-76.
• [28]Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, et al.: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
• [29]Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L, et al.: Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am J Transl Res 2012, 4:14-23.
• [30]Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al.: MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
• [31]Vogt M, Munding J, Gruner M, Liffers ST, Verdoodt B, Hauk J, et al.: Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 2011, 458:313-322.
• [32]Cowan LA, Talwar S, Yang AS: Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics 2010, 2:71-86.
• [33]Hermeking H: The miR-34 family in cancer and apoptosis. Cell Death Differ 2010, 17:193-199.
• [34]Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol 2011, 6:479-507.
• [35]Wu W, Sun M, Zou GM, Chen J: MicroRNA and cancer: Current status and prospective. Int J Cancer 2007, 120:953-960.
• [36]Jordan CT, Guzman ML, Noble M: Cancer stem cells. N Engl J Med 2006, 355:1253-1261.